10-K: LENSAR's 2025: Revenue Up, Merger Off, Losses Continue

LENSAR, Inc. reported a 9% increase in total revenue to $58.4 million for fiscal year 2025, alongside continued net losses of $34.3 million and the termination of its merger agreement with Alcon.

Summary

• Total revenue increased 9% to $58.4 million in 2025 from $53.5 million in 2024.
• Net loss increased to $34.3 million in 2025 from $31.4 million in 2024, with an accumulated deficit of $177.6 million as of December 31, 2025.
• Operating losses are expected to continue for the near-term future as the company invests in commercial and clinical infrastructure and R&D.
• The merger agreement with Alcon Research, LLC was terminated on March 16, 2026, following FTC's intention to enjoin the merger.
• LENSAR will retain a $10.0 million cash deposit from Alcon due to the merger termination, which will be recorded as other income in Q1 2026.
• Acquisition-related costs of $17.1 million were incurred in 2025 due to the terminated merger, with $4.3 million to be reduced and $5.0 million reclassified to long-term accounts payable in Q1 2026.
• Procedure volume increased to 206,014 in 2025 from 169,506 in 2024.
• The ALLY Robotic Cataract Laser System (ALLY System) received FDA clearance in June 2022 and launched in August 2022, also holding regulatory clearance in the EU, India, Taiwan, South Korea, and other countries.
• The company held approximately 18.0% market share in laser cataract surgery in 2024 by revenue.
• Each ALLY System averaged 624 procedures in 2025, outperforming the estimated industry average of 496 procedures per year per installed device.
• As of December 31, 2025, the company had approximately 435 systems installed in 17 countries.
• Cash and cash equivalents were $12.974 million as of December 31, 2025.
• A Priority Credit Line Agreement with Wells Fargo Bank, N.A. was entered into in March 2026, providing a revolving credit facility secured by a designated brokerage account.
• The company expects current cash and cash equivalents, together with cash generated from future sales and leases, to be sufficient for at least one year from the financial statement issuance date (March 31, 2026).

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a challenging period for LENSAR, marked by increasing losses and significant cash burn, despite revenue growth and strong product performance metrics. The terminated merger and associated costs, coupled with ongoing macroeconomic and regulatory uncertainties, create a cautious outlook.

Positives

• Total revenue increased by 9% year-over-year to $58.4 million in 2025.
• Product revenue increased by 12% ($4.9 million) in 2025, primarily driven by increased procedure volume.
• Service revenue increased by 17% ($0.8 million) in 2025 due to the increased number of Systems placements.
• Procedure volume grew significantly to 206,014 in 2025 from 169,506 in 2024, indicating strong product utilization.
• The ALLY System demonstrated strong market acceptance, with each system averaging 624 procedures in 2025, significantly exceeding the estimated industry average of 496 procedures per year.
• The company achieved an estimated 18.0% market share in laser cataract surgery in 2024 by revenue.
• The ALLY System is cleared for marketing in major global markets including the U.S., EU, India, Taiwan, and South Korea, providing broad commercial reach.
• The company will retain a $10.0 million cash deposit from the terminated Alcon merger agreement, boosting liquidity.
• A new Priority Credit Line Agreement with Wells Fargo Bank, N.A. provides a revolving credit facility, enhancing financial flexibility.
• The company's intellectual property portfolio is robust, with 292 issued patents and 105 pending applications globally as of December 31, 2025.
• Management believes current cash and cash equivalents, along with future sales and leases, are sufficient to support operations for at least one year.

Negatives

• Net loss increased to $34.3 million in 2025 from $31.4 million in 2024, indicating a worsening profitability trend.
• The accumulated deficit reached $177.6 million as of December 31, 2025, highlighting a history of operating losses.
• Operating losses are expected to continue for the near-term future.
• Acquisition-related costs of $17.1 million were incurred in 2025 due to the terminated merger, impacting profitability.
• Lease revenue decreased by 10% ($0.8 million) in 2025, primarily due to decreased leased LLS.
• Tariffs on imported raw materials for ALLY Systems and PIDs have increased product costs by at least 10%, negatively impacting gross profit margin as these costs have not been passed on to customers.
• The change in fair value of warrant liabilities negatively impacted net loss by $10.3 million in 2025 and $21.4 million in 2024.
• Cash used in operating activities increased significantly to $14.8 million in 2025 from $2.3 million in 2024, indicating increased cash burn.
• Inventory levels increased substantially to $21.520 million in 2025 from $11.428 million in 2024, partly due to reduced distributor activity following the merger announcement.
• One customer accounted for 13% of revenue in 2025, indicating a concentration risk.
• The ownership by NR-GRI and its affiliates (45.4% voting power as of December 31, 2025) limits the company's ability to undertake certain corporate actions without their consent, including capital raises over $1.0 million or debt over $1.0 million.
• The Series A Redeemable Convertible Preferred Stock ranks senior to common stock in distributions and liquidation, potentially affecting the residual value of common stock.
• The company does not carry cyber insurance, exposing it to potential losses for damages or fines in an amount exceeding its resources from cybersecurity incidents.

Risks

• The termination of the Merger Agreement could negatively impact business, financial condition, results of operations, or stock price.
• Potential shareholder litigation related to the terminated Merger Agreement could result in damages and increased costs.
• Economic uncertainty, including increased inflation, rising interest rates, and tariffs, could adversely affect revenue, profit margins, cash flow, and liquidity.
• Inability to achieve or sustain profitability, as the company expects to incur operating losses for the near-term future.
• Commercial success of the ALLY System depends on additional regulatory clearances/certifications and market acceptance, which is not assured.
• Patients may be unwilling to pay the price difference for advanced cataract procedures using laser systems, as these are typically not covered by Medicare or other third-party payors.
• Inability to effectively grow the U.S. sales and marketing organization or maintain/grow an effective network of international distributors could adversely affect business prospects.
• Future capital needs are uncertain, and additional funds may not be available on acceptable terms or at all, potentially leading to dilution for existing stockholders if equity is issued.
• Material disruption to the supply or manufacture of Systems or component parts, including from supply chain shortages, price increases, or geopolitical conflicts (e.g., China/Taiwan semiconductor supply), could negatively affect operating results.
• Intense competition from larger, more established medical device companies with greater resources and existing IOL portfolios.
• Exposure to international business risks, including difficulties in managing operations, increased competition, longer payment cycles, reduced intellectual property protection, tariffs, currency fluctuations, and political instability.
• Credit risk from customers, especially those leasing systems or financing through product utilization, could result in material losses.
• Inability to accurately forecast customer demand and manage inventory levels, potentially leading to missed revenue opportunities or increased excess/obsolete inventory.
• Failure to secure adequate coverage or reimbursement by government or other third-party payors for procedures using the ALLY System or future products, or changes in current coverage/reimbursement, could materially impact revenue and future growth.
• Product liability suits could cause substantial liabilities, limit sales, and interfere with commercialization.
• Extensive government regulation and oversight in the U.S. and abroad (FDA, EU MDR, UK Medical Devices Regulations), with failure to comply leading to enforcement actions, fines, or product recalls.
• Delays or failure in receiving necessary regulatory clearances, certifications, or approvals for future products or modifications to current products.
• Misuse or off-label use of products could harm reputation, lead to product liability suits, or result in costly investigations/sanctions.
• Products may cause or contribute to adverse medical events or malfunctions requiring reporting to regulatory authorities, with failure to report leading to sanctions.
• Inability to obtain and maintain international regulatory registrations, clearances, certifications, or approvals.
• Lengthy, expensive, and uncertain clinical trial processes, with results of earlier studies not necessarily predictive of future outcomes.
• Legislative or regulatory reforms (e.g., ACA, OBBBA, EU AI Act) could increase difficulty and cost of commercialization or affect pricing.
• Disruptions at government agencies (FDA) and notified bodies (EU) due to funding shortages, staffing limitations, or global health concerns could delay product reviews.
• Subject to federal, state, and foreign healthcare fraud and abuse laws (Anti-Kickback Statute, False Claims Act, Sunshine Act), with violations leading to significant penalties.
• Subject to anti-corruption and anti-bribery laws (FCPA, U.K. Bribery Act), with violations leading to severe sanctions.
• Employees, contractors, and distributors may engage in misconduct or noncompliance with regulatory standards.
• Inability to obtain, maintain, and protect intellectual property rights (patents, trademarks, trade secrets) could allow competitors to use technologies and erode competitive advantage.
• Potential for intellectual property litigation or administrative proceedings, which are costly and could interfere with business.
• Failure to protect the confidentiality of proprietary information (trade secrets, know-how) could harm business and competitive position.
• Inability to protect intellectual property rights throughout the world, especially in countries with weaker IP laws.
• Claims of misappropriation of third-party intellectual property or breach of non-competition agreements by employees/consultants.
• Failure of third parties (suppliers, distributors, CROs) to meet contractual or regulatory obligations.
• Cybersecurity risks, including technology failures, cyber-attacks, data breaches, and ransomware, could harm reputation, disrupt operations, and lead to significant costs and liabilities.
• The evolving regulatory framework governing AI Technologies poses significant technological and legal risks, including potential for deficient AI-generated content, data quality issues, and increased compliance costs.
• The large number of shares eligible for public sale could depress the market price of common stock.
• As a smaller reporting company, reduced disclosure requirements might make common stock less attractive to investors.
• The company's charter documents and Delaware law could discourage takeover attempts and lead to management entrenchment.
• Designation of certain courts as sole and exclusive forums for litigation could limit stockholders' ability to obtain a favorable judicial forum.
• The trading price of common stock is likely to be volatile.
• Obligation to develop and maintain proper and effective internal control over financial reporting is burdensome and costly.
• Disclosure controls and procedures may not prevent or detect all errors or acts of fraud.
• If securities or industry analysts do not continue to publish research or publish inaccurate/unfavorable research, stock price and trading volume could decline.
• Scrutiny and stakeholder expectations regarding environmental, social, and governance (ESG) matters may cause expenses and liabilities.
• Ability to use net operating loss carryforwards to offset future taxable income may be subject to certain limitations due to ownership changes (e.g., Section 382).

Future Outlook

LENSAR expects to continue incurring operating losses and cash outflows for the near-term future as it builds commercial and clinical infrastructure and invests in research and development. The company anticipates annual revenue and selling, general and administrative expenses to increase with the expansion of ALLY System placements. LENSAR aims to return to a more normal system placement cadence, though this may take several quarters. Future liquidity needs will be largely determined by the success of commercial efforts, additional regulatory clearances for the ALLY System, and ongoing macroeconomic conditions. The overall cost of the ALLY System may increase due to inflationary pressures and component pricing. The global cataract surgery market is projected to grow from 33.1 million procedures in 2025 to 39.6 million in 2030, with laser-assisted procedures expected to increase from 1 million to 1.2 million globally in the same period. New competitive products, such as Bausch + Lomb's anticipated SeeLyra laser in H2 2026, are expected to enter the market. The regulatory landscape for AI Technologies is rapidly evolving, with the EU AI Act's substantive requirements expected to apply from August 2, 2026 (with a proposed extension to December 2, 2027) and the revised EU Product Liability Directive to be implemented by December 2026. New UK legislation on pre-market medical device requirements and a consultation on indefinite recognition of certain medical devices in Great Britain are expected in 2026. The European Commission's targeted revision proposal of the MDR is not expected to be adopted before 2027. The company expects additional U.S. federal healthcare reform measures to be adopted in the future and plans to continue adding to its patent portfolio for the ALLY System.

Management Comments

• "We believe the cumulative effect of these technologies results in laser systems that can be quickly and efficiently integrated into a surgeons existing practice, is easy to use and provides surgeons the ability to deliver improved visual outcomes with enhanced precision and the ability to do so consistently."
• "We believe the ALLY System's surgical efficiencies and combined functions could help drive broader penetration into the cataract surgery market and could potentially create a paradigm shift in the treatment of cataracts and management of astigmatism in cataract surgery."
• "We believe our disruptive technology platform has enabled us to rapidly take market share in a highly competitive market."
• "We believe the clinical data supporting the effectiveness of our laser system in assisting surgeons to achieve desired outcomes will motivate additional patients to seek, and additional surgeons to offer, these more advanced procedures that include implantation of a premium IOL."
• "We believe these innovations, which are intended to improve patient flow and efficiency, have the potential to allow surgeons to perform more premium procedures each surgery day, helping them to meet the expected increase in demand for cataract/refractive lens exchange surgical procedures."
• "We are committed to revolutionizing refractive eye surgery. As a global leader in next generation, robotic laser for cataract surgery, our success depends on talented and motivated individuals who share our passion for making a difference in patients lives."
• "Management believes the Company’s cash, cash equivalents, and investments on hand, together with cash generated from the future sale and lease of products, will provide sufficient funds for its operating, investing, and financing cash flows for a period of at least twelve months from the date of issuance of these financial statements."

Industry Context

StockSavvy.ai notes that the global cataract surgery market is projected for significant growth, from 33.1 million procedures in 2025 to 39.6 million in 2030, driven by an aging population and new technologies like laser systems and innovative IOLs. Despite this growth, laser-assisted procedures currently represent a small fraction (1 million in 2025, growing to 1.2 million in 2030), indicating a substantial untapped market for advanced solutions. The industry is highly competitive, with major players like Alcon, Bausch + Lomb, Johnson & Johnson, and Carl Zeiss AG, who possess greater resources and established product lines, including their own IOLs, which LENSAR lacks. The increasing focus on patient-pay advanced refractive procedures, driven by declining reimbursement for standard cataract surgery, aligns with LENSAR's strategy for its ALLY System. However, the entry of new competitive products, such as Bausch + Lomb's anticipated SeeLyra laser in H2 2026, will intensify market competition.

Comparison to Industry Standards

• LENSAR's ALLY System averaged 624 procedures per installed device in 2025, significantly outperforming the estimated industry average of 496 procedures per year per installed device, demonstrating superior utilization.
• Clinical data presented at the 2023 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting showed 99% of patients receiving a toric IOL using the ALLY System achieved refractive correction within 0.5 diopters of target, indicating high precision and improved visual outcomes compared to traditional methods.
• The ALLY System's compact design and dual-modality laser enable sterile cataract surgery in a single operating room, offering workflow time savings of up to 17 minutes for surgeons, 19 minutes for surgical staff, and 51 minutes for patients, a notable efficiency improvement over competing laser systems that often require patient movement between rooms.
• LENSAR's estimated 18.0% market share in laser cataract surgery in 2024 (by revenue) positions it as a significant player against established multinational medical device companies such as Alcon Inc., Bausch + Lomb, Carl Zeiss AG, AMO (Johnson & Johnson), and Ziemer Ophthalmic Systems AG.
• The company's focus on addressing corneal astigmatism, which affects an estimated 70-90% of cataract patients, targets a substantial patient population often not fully addressed by standard cataract procedures, offering a differentiated value proposition.

Corporate Governance

Legal Proceedings

• Shareholder litigation related to the termination of the Merger Agreement, including demand letters alleging deficiencies in proxy statements and a verified complaint filed in the Delaware Court of Chancery seeking to inspect corporate books and records.
• General involvement in various legal proceedings relating to matters incidental to the terminated Merger Agreement and in the ordinary course of business, including intellectual property, commercial, product liability, employment, class action, whistleblower, and other litigation and claims, and governmental and other regulatory investigations and proceedings.

Related Party Transactions

• In May 2023, the company completed a Private Placement with NR-GRI Partners, LP (an affiliate of North Run Capital, LP), selling 20,000 shares of Series A Redeemable Convertible Preferred Stock and warrants to purchase 4.4 million common shares for $20.0 million.
• Thomas B. Ellis and Todd B. Hammer, co-managing partners of North Run, joined the company's Board of Directors following the 2023 Annual Meeting of Stockholders.
• As of December 31, 2025, North Run and its affiliates held 45.4% of the voting power of the company's capital stock.
• The terms of the Series A Redeemable Convertible Preferred Stock require NR-GRI's consent for certain corporate actions, including liquidation, mergers, acquisitions over $1.0 million, debt over $1.0 million, changes in business line, or certain related-party transactions.
• In June 2023, the company entered into an international distribution agreement in India with a company owned by an employee at that time; this related party relationship ended on April 1, 2024.

Stakeholder Impact

• Shareholders: Potential dilution from future equity raises; limited influence on corporate matters due to concentrated ownership by NR-GRI; reliance on stock appreciation for return as no cash dividends are anticipated; potential volatility in stock price due to various factors including market fluctuations and analyst reports; potential negative impact from shareholder litigation related to the terminated merger.
• Employees: Uncertainty regarding future due to terminated merger potentially impacting retention or hiring of key employees; increased compensation levels for recruitment and retention efforts; stock-based compensation plans align interests with stockholders; comprehensive benefits package including health insurance, retirement plan, and disability insurance.
• Customers: Potential for increased product costs due to tariffs not being passed on; potential delays in product delivery due to supply chain disruptions; reliance on third-party payors for reimbursement of advanced procedures, which may not be fully covered; exposure to credit risk if customers fail to make lease payments.
• Suppliers: Risk of material disruption if single-sourced suppliers cease provision or face supply chain issues; increased costs for component parts due to inflationary pressures and tariffs.
• Creditors: Potential impact on ability to obtain additional capital on favorable terms due to economic uncertainty and increased interest rates; debt financing may involve restrictive covenants.

Next Steps

• Continue building commercial and clinical infrastructure.
• Pursue further FDA and other regulatory body clearance or certification of the ALLY System.
• Further commercial launch of the ALLY System in additional jurisdictions.
• Invest in research and development for product enhancements.
• Expand the size and geographic breadth of the U.S. sales and marketing management team.
• Expand the network of independent distributors in additional international markets.
• Add additional field sales professionals and clinical outcome specialists in the U.S.
• Expand marketing support and commitment to physician and staff training programs.
• Continue to evaluate the impact of the One Big Beautiful Bill Act (OBBBA) tax law changes on future periods.
• Adapt to new or changing executive orders and policies relating to AI Technologies.
• Monitor and adapt to the evolving regulatory framework for AI Technologies, including the EU AI Act and the revised EU Product Liability Directive.
• Monitor the impact of the Supreme Court tariff ruling and any additional tariffs.
• Reduce acquisition-related costs and accounts payable by approximately $4.3 million during the three months ending March 31, 2026.
• Reclassify $5.0 million of accounts payable from current to long-term during the three months ending March 31, 2026, based on extended payment terms.
• Record the $10.0 million Merger Deposit as Other Income for the three months ending March 31, 2026.
• File the definitive proxy statement for the 2026 annual meeting of stockholders within 120 days of December 31, 2025.

Key Dates

Recommendation

StockSavvy.ai recommends a "Hold" position for LENSAR, Inc. While the company demonstrated solid revenue growth and impressive ALLY System adoption and market share gains, the significant increase in net losses and cash used in operating activities, coupled with the termination of the Alcon merger, introduces considerable financial uncertainty. The retention of the $10.0 million deposit provides some liquidity, but the ongoing need for future capital, exposure to macroeconomic headwinds like inflation and tariffs, and intense competition warrant a cautious stance until there is clearer evidence of sustainable profitability and reduced cash burn.

Keywords

LENSAR, ALLY System, Cataract Surgery, Femtosecond Laser, Ophthalmic Devices, Medical Device, Robotic Surgery, Astigmatism Correction, IOLs, SEC Filing, 10-K, Financial Report, Healthcare Technology, AI in Healthcare, Corporate Governance, Risk Factors, Nasdaq, LNSR